e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Difficult asthma in children: diagnostic and therapeutic challenges
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Ciclosporin as a steroid sparing agent in children with difficult to treat asthma
L. Chapell, C. Tranter, T. Hilliard (Bristol, United Kingdom)
Source:
Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Session:
Difficult asthma in children: diagnostic and therapeutic challenges
Session type:
Oral Presentation
Number:
3278
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Chapell, C. Tranter, T. Hilliard (Bristol, United Kingdom). Ciclosporin as a steroid sparing agent in children with difficult to treat asthma. Eur Respir J 2009; 34: Suppl. 53, 3278
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?
Source: Eur Respir J 2011; 38: 947-958
Year: 2011
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Source: Breathe 2010; 6: 365
Year: 2010
A retrospective analysis of methotrexate therapy as a steroid sparing agent within a UK severe asthma clinic
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012
Mild asthma. Is constant therapy by inhaled steroids necessary?
Source: Eur Respir J 2006; 28: Suppl. 50, 500s
Year: 2006
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004
Children with mild asthma: do they benefit from inhaled corticosteroids?
Source: Eur Respir J 2002; 20: 1470-1475
Year: 2002
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
How effective are oral steroids in asthma action plans?
Source: International Congress 2017 – Asthma management
Year: 2017
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018
Year: 2019
Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Are non-valved spacers useful for long-term treatment with inhaled steroids in asthmatic young children?
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Adrenal insufficiency in asthma treated with high/low systemic corticosteroids in the past and in those who sucessfully discontinued systemic corticosteroids after treatment with omalizmab.
Source: International Congress 2017 – Management of asthma in different situations
Year: 2017
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Oral corticosteroids for asthma usually prescribed by non-specialists
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept